Nicolas L Dzamko

List of Publications by Year
in descending order

56 papers	4,162 citations	136885 32 h-index	175177 52 g-index
56 all docs	56 docs citations	56 times ranked	5043 citing authors

#	Article	IF	Citations
1	Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology, 2011, 7, 203-205.	3.9	380
2	14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochemical Journal, 2010, 430, 393-404.	1.7	355
3	Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochemical Journal, 2010, 430, 405-413.	1.7	355
4	CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nature Medicine, 2006, 12, 541-548.	15.2	250
5	Toll-like receptor 2 is increased in neurons in Parkinsonâ€™s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathologica, 2017, 133, 303-319.	3.9	200
6	Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochemical Journal, 2009, 424, 47-60.	1.7	186
7	The IkappaB Kinase Family Phosphorylates the Parkinsonâ€™s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling. PLoS ONE, 2012, 7, e39132.	1.1	183
8	Inflammation is genetically implicated in Parkinsonâ€™s disease. Neuroscience, 2015, 302, 89-102.	1.1	182
9	AMPK Î²1 Deletion Reduces Appetite, Preventing Obesity and Hepatic Insulin Resistance. Journal of Biological Chemistry, 2010, 285, 115-122.	1.6	154
10	Whole Body Deletion of AMP-activated Protein Kinase Î²2 Reduces Muscle AMPK Activity and Exercise Capacity. Journal of Biological Chemistry, 2010, 285, 37198-37209.	1.6	145
11	Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia, 2004, 47, 1306-1313.	2.9	126
12	AMPKâ€independent pathways regulate skeletal muscle fatty acid oxidation. Journal of Physiology, 2008, 586, 5819-5831.	1.3	121
13	Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity1. Hepatology, 2010, 52, 1632-1642.	3.6	89
14	LRRK2â€mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients. Movement Disorders, 2019, 34, 406-415.	2.2	83
15	Reduced glucocerebrosidase activity in monocytes from patients with Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 15446.	1.6	82
16	Increased peripheral inflammation in asymptomatic leucineâ€rich repeat kinase 2 mutation carriers. Movement Disorders, 2016, 31, 889-897.	2.2	76
17	Autophagy activation promotes clearance of Î±-synuclein inclusions in fibril-seeded human neural cells. Journal of Biological Chemistry, 2019, 294, 14241-14256.	1.6	76
18	AMPKâ€dependent hormonal regulation of wholeâ€body energy metabolism. Acta Physiologica, 2009, 196, 115-127.	1.8	75

#	Article	IF	Citations
19	ParkinsonÃ¢â,¬â„¢s disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in Molecular Neuroscience, 2014, 7, 57.	1.4	73
20	Metformin Prevents the Development of Acute Lipid-Induced Insulin Resistance in the Rat Through Altered Hepatic Signaling Mechanisms. Diabetes, 2004, 53, 3258-3266.	0.3	71
21	Contraction-induced skeletal muscle FAT/CD36 trafficking and FA uptake is AMPK independent. Journal of Lipid Research, 2011, 52, 699-711.	2.0	67
22	Parkinsonâ€™s progression prediction using machine learning and serum cytokines. Npj Parkinson's Disease, 2019, 5, 14.	2.5	63
23	Rosiglitazone Treatment Enhances Acute AMP-Activated Protein Kinase-Mediated Muscle and Adipose Tissue Glucose Uptake in High-Fat-Fed Rats. Diabetes, 2006, 55, 2797-2804.	0.3	59
24	LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 177-189.	0.8	49
25	Recent Developments in LRRK2-Targeted Therapy for Parkinsonâ€™s Disease. Drugs, 2019, 79, 1037-1051.	4.9	48
26	Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. European Journal of Medicinal Chemistry, 2013, 70, 758-767.	2.6	45
27	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. Journal of Parkinson's Disease, 2013, 3, 145-152.	1.5	44
28	LRRK2 and the Immune System. Advances in Neurobiology, 2017, 14, 123-143.	1.3	42
29	LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. Movement Disorders, 2017, 32, 423-432.	2.2	39
30	An emerging role for LRRK2 in the immune system. Biochemical Society Transactions, 2012, 40, 1134-1139.	1.6	36
31	Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Brain, 2018, 141, 486-495.	3.7	36
32	Leucine Rich Repeat Kinase 2 and Innate Immunity. Frontiers in Neuroscience, 2020, 14, 193.	1.4	36
33	Inhibitor treatment of peripheral mononuclear cells from Parkinsonâ€™s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports, 2016, 6, 31391.	1.6	32
34	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 2015, 95, 29-34.	2.6	31
35	Immune responses in the Parkinson's disease brain. Neurobiology of Disease, 2022, 168, 105700.	2.1	30
36	DNA extraction from fresh-frozen and formalin-fixed, paraffinembedded human brain tissue. Neuroscience Bulletin, 2013, 29, 649-654.	1.5	25

#	Article	IF	Citations
37	Lipid pathway dysfunction is prevalent in patients with Parkinsonâ€™s disease. Brain, 2022, 145, 3472-3487.	3.7	25
38	Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity. Movement Disorders, 2021, 36, 2719-2730.	2.2	22
39	Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease. PLoS ONE, 2016, 11, e0160501.	1.1	19
40	Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. Npj Parkinson's Disease, 2022, 8, 34.	2.5	18
41	Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease. Movement Disorders, 2021, 36, 1451-1455.	2.2	17
42	Singleâ€Molecule Counting Coupled to Rapid Amplification Enables Detection of Î±â€Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients. Angewandte Chemie - International Edition, 2021, 60, 11874-11883.	7.2	17
43	Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice. Neurobiology of Disease, 2018, 120, 76-87.	2.1	16
44	Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinsonâ€™s Disease Patients. Journal of Parkinson's Disease, 2021, 11, 1761-1772.	1.5	15
45	WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinsonâ€™s Disease Monocytes. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	13
46	Singleâ€Molecule Counting Coupled to Rapid Amplification Enables Detection of Î±â€Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients. Angewandte Chemie, 2021, 133, 11981-11990.	1.6	11
47	Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinsonâ€™s Disease Patient Monocytes and Inversely Correlates with Motor Severity. Journal of Parkinson's Disease, 2021, 11, 1157-1165.	1.5	11
48	LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Neurobiology of Disease, 2020, 144, 105049.	2.1	10
49	Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation. Neurobiology of Disease, 2021, 157, 105426.	2.1	7
50	A small molecule toll-like receptor antagonist rescues Î±-synuclein fibril pathology. Journal of Biological Chemistry, 2022, 298, 102260.	1.6	6
51	Unlocking the secrets of LRRK2 function with selective kinase inhibitors. Future Neurology, 2013, 8, 347-357.	0.9	4
52	Sex-specific lipid dysregulation in the <i>Abca7</i> knockout mouse brain. Brain Communications, 2022, 4, .	1.5	4
53	Flow Cytometry Measurement of Glucocerebrosidase Activity in Human Monocytes. Bio-protocol, 2020, 10, e3572.	0.2	2
54	Investigating lymphocyte populations in patients with Parkinsonâ€™s disease. Annals of Translational Medicine, 2020, 8, 276-276.	0.7	1

#	Article	IF	Citations
55	LRRK2 mutations, regulation and 14â€“3â€“3 protein interaction: implications for Parkinsonâ€™s disease. Future Neurology, 2011, 6, 5-8.	0.9	0
56	Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of Î±-Synuclein Autoantibodies in Human Plasma. Bioconjugate Chemistry, 2022, , .	1.8	0